Press release
Nonalcoholic Steatohepatitis Market Forecasted to Hit USD 44.5 Billion by 2034
Nonalcoholic Steatohepatitis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71163
NASH has rapidly become one of the most pressing global public health concerns, with prevalence rising sharply due to increasing obesity and diabetes rates. Despite its widespread impact, NASH is often underdiagnosed, creating a substantial gap between the true patient pool and the treated population. Over the next decade, rising adoption of non-invasive diagnostics and new drug approvals are expected to redefine the NASH patient pool market.
Market Overview
• Market Size (2024): USD 19.7 billion
• Forecast (2034): USD 44.5 billion
• CAGR (2025-2034): 8.5%
The NASH patient pool market is growing steadily as diagnosis rates improve and healthcare systems respond to the metabolic syndrome epidemic. Lifestyle interventions and pipeline drug launches will further expand the treated population.
Key Highlights:
• Rising global prevalence of obesity and diabetes significantly expanding the NASH patient pool.
• Growing adoption of non-invasive diagnostics (FibroScan, MRI-PDFF, biomarkers).
• Underdiagnosis remains a challenge - only a small percentage of patients are identified early.
• Pharmaceutical innovation will shift more patients from the undiagnosed to treated pool.
Segmentation Analysis
By Product Type:
• Diagnostic Tools
o Imaging (MRI, FibroScan, Ultrasound Elastography)
o Biomarker-Based Tests
o Liver Biopsy (gold standard but invasive)
• Lifestyle Interventions
• Pharmaceutical Therapies (Pipeline)
o FXR Agonists
o PPAR Agonists
o GLP-1 Receptor Agonists
o THR-β Agonists
• Supportive Care
By Platform:
• Diagnostics
• Small Molecules
• Biologics
• Combination Therapies
By Technology:
• Imaging Technologies
• Biomarker Platforms
• AI-Driven Predictive Diagnostics
By End Use:
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Research Institutes
By Application:
• Obese/Diabetic Patient Subgroup
• Early-Stage Fibrosis (F1-F2)
• Advanced Fibrosis (F3-F4)
• Cirrhosis Risk & HCC Surveillance
• Clinical Research Patient Pools
Segmentation Summary:
Diagnostics form the foundation of the NASH patient pool market, with imaging and biomarkers replacing liver biopsy for early identification. Pharmaceutical therapies, once approved, will significantly expand the treated patient segment, especially among advanced fibrosis cases.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71163/nonalcoholic-steatohepatitis-nash-patient-pool-market
Regional Analysis
North America
• Largest market with ~47% share in 2024.
• High obesity and diabetes prevalence driving massive NASH patient pool.
• Strong adoption of non-invasive diagnostics and clinical trial participation.
Europe
• Accounts for ~28% share.
• Germany, UK, and France leading in diagnosis and research activity.
• Rising prevalence of metabolic syndrome expanding patient base.
Asia-Pacific
• Fastest-growing region with CAGR of ~9.6%.
• High prevalence of obesity and diabetes in China, India, and Japan.
• Large undiagnosed population offers significant market potential.
Middle East & Africa
• Smaller market share, but increasing incidence due to changing dietary patterns.
• Limited diagnostic infrastructure remains a challenge.
Latin America
• Brazil and Mexico drive regional growth.
• Expanding healthcare access and awareness gradually improving diagnosis rates.
Regional Summary:
North America and Europe dominate today due to advanced diagnostic infrastructure, while Asia-Pacific will be the fastest-growing region as lifestyle-related diseases expand the patient pool.
Market Dynamics
Key Growth Drivers:
• Rising prevalence of obesity, diabetes, and metabolic syndrome.
• Expanding adoption of non-invasive diagnostics for early detection.
• Growing clinical trial activity and imminent drug approvals.
• Government focus on reducing long-term liver disease burden.
Key Challenges:
• High underdiagnosis rates limiting early intervention.
• Lack of currently approved pharmacological therapies.
• High costs of advanced imaging and diagnostics in emerging markets.
• Limited patient awareness outside developed countries.
Latest Trends:
• Development of AI-driven predictive models for early diagnosis.
• Integration of NASH screening in diabetic and obesity clinics.
• Pipeline therapies (FXR, PPAR, GLP-1, THR-β agonists) nearing approvals.
• Shift toward combination approaches addressing fibrosis and metabolic dysfunction.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71163
Competitor Analysis
Major Players in the Market:
• Madrigal Pharmaceuticals
• Intercept Pharmaceuticals
• Novo Nordisk
• Genfit
• Gilead Sciences, Inc.
• Novartis AG
• Pfizer Inc.
• Bristol Myers Squibb (BMS)
• AstraZeneca plc
• Inventiva Pharma
Competitive Summary:
Madrigal, Intercept, and Novo Nordisk are leading the race with late-stage drug candidates targeting different disease pathways. Gilead and Novartis are pursuing combination regimens, while Novo Nordisk's GLP-1 receptor agonists offer cross-therapeutic potential. Diagnostics leaders are collaborating with pharma companies to expand the identified patient pool.
Conclusion
The Nonalcoholic Steatohepatitis (NASH) Patient Pool Market, valued at USD 19.7 billion in 2024, is projected to reach USD 44.5 billion by 2034, growing at a CAGR of 8.5%. Rising obesity and diabetes prevalence, better diagnostics, and pipeline drug approvals will significantly expand the patient pool over the next decade.
Key Takeaways:
• NASH is rapidly becoming one of the most significant global liver health challenges.
• Diagnostics and patient identification remain critical growth drivers.
• North America leads today, while Asia-Pacific will show the fastest growth.
• Upcoming drug approvals will move patients from the undiagnosed to treated pool.
Over the next decade, the NASH patient pool market will evolve through early diagnosis, non-invasive testing, and disease-modifying therapies, unlocking major opportunities for healthcare providers, pharmaceutical companies, and diagnostic innovators.
This report is also available in the following languages : Japanese (非アルコール性脂肪肝炎(NASH)患者プール市場), Korean (비알코올성 지방간염(NASH) 환자 풀 시장), Chinese (非酒精性脂肪性肝炎(NASH)患者池市场), French (Marché des patients atteints de stéatohépatite non alcoolique (NASH)), German (Markt für Patientenpools mit nichtalkoholischer Steatohepatitis (NASH)), and Italian (Mercato dei pazienti con steatoepatite non alcolica (NASH)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71163/nonalcoholic-steatohepatitis-nash-patient-pool-market#request-a-sample
Our More Reports:
Diffuse cutaneous systemic sclerosis Market
https://exactitudeconsultancy.com/reports/71407/diffuse-cutaneous-systemic-sclerosis-market
Dyschromia Market
https://exactitudeconsultancy.com/reports/71409/dyschromia-market
Erythema Market
https://exactitudeconsultancy.com/reports/71411/erythema-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nonalcoholic Steatohepatitis Market Forecasted to Hit USD 44.5 Billion by 2034 here
News-ID: 4159941 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for NASH
The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking…
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
